Literature DB >> 21878227

Histone deacetylase inhibitors enhance endothelial cell sprouting angiogenesis in vitro.

Guang Jin1, Dirk Bausch, Thomas Knightly, Zhengcai Liu, Yongqing Li, Baoling Liu, Jennifer Lu, Wei Chong, George C Velmahos, Hasan B Alam.   

Abstract

BACKGROUND: Treatment with histone deacetylases inhibitors (HDACi) such as valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) has been shown to improve survival after lethal insults through mechanisms that are incompletely understood. Cell survival under adverse conditions requires a healthy network of capillaries to ensure adequate oxygen delivery. Angiogenic activation of endothelial cells to migrate and form sprouts is associated with characteristic changes in gene expression profiles. Because HDACi can modulate expression of various genes involved in angiogenic activity, we investigated the effect of these agents on capillary-like sprout formation in this study.
METHODS: Human umbilical vein endothelial cells (HUVECs) were cultured as multicellular spheroids within a type I collagen matrix, which promotes formation of sprouts resembling angiogenesis in vitro. HUVECs were cultured as multicellular spheroids within a type I collagen matrix, which promotes formation of sprouts (in vitro angiogenesis). Cells were cultured under the following conditions: Control (no growth factors); VPA (1 mmol/L); vascular endothelial growth factor (VEGF; 10 ng/mL); VPA + VEGF; SAHA (5 mmol/L), and SAHA + VEGF. After 24 hours of treatment, the length of spheroid sprouting and cell migration was assessed quantitatively. The levels of acetylated histone H3, phosphor-extracellular signal-regulated kinase (ERK)1/2, and β-catenin in HUVECs were measured by Western blotting at 6 hours after treatment.
RESULTS: High levels of acetylated histone H3 were detected in VPA and SAHA treated-groups. Compared with the VEGF-alone treated group (2379 ± 147.1 μm), the spheroid sprouting was 1.7 times increased with VPA and VEGF combined treatment (3996 ± 192.5 μm; P < .01). Cell migrations did not show a significant difference after addition of VPA, whereas SAHA suppressed migration. Expression of β-catenin was significantly increased by VPA and SAHA treatments. Addition of VPA greatly enhanced expression of phosphor-ERK1/2.
CONCLUSION: Exposure of HUVECs to VPA and SAHA increased the expression of β-catenin and enhanced spheroid sprout formation in vitro. Modulation of HDAC-dependent pathways may offer a novel approach to alter angiogenic processes and provide a useful therapeutic target.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21878227      PMCID: PMC3164968          DOI: 10.1016/j.surg.2011.07.001

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  27 in total

Review 1.  The human histone deacetylase family.

Authors:  S G Gray; T J Ekström
Journal:  Exp Cell Res       Date:  2001-01-15       Impact factor: 3.905

Review 2.  Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.

Authors:  Timothy A McKinsey; Eric N Olson
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  VEGF and endothelial guidance in angiogenic sprouting.

Authors:  Holger Gerhardt
Journal:  Organogenesis       Date:  2008-10       Impact factor: 2.500

Review 4.  Endothelial cell survival and apoptosis in the tumor vasculature.

Authors:  W Liu; S A Ahmad; N Reinmuth; R M Shaheen; Y D Jung; F Fan; L M Ellis
Journal:  Apoptosis       Date:  2000-10       Impact factor: 4.677

5.  Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells.

Authors:  M Michaelis; T Suhan; U R Michaelis; K Beek; F Rothweiler; L Tausch; O Werz; D Eikel; M Zörnig; H Nau; I Fleming; H W Doerr; J Cinatl
Journal:  Cell Death Differ       Date:  2006-03       Impact factor: 15.828

Review 6.  Histone deacetylases: anti-angiogenic targets in cancer therapy.

Authors:  Denis Mottet; Vincent Castronovo
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

7.  Valproic acid inhibits angiogenesis in vitro and in vivo.

Authors:  Martin Michaelis; U Ruth Michaelis; Ingrid Fleming; Tatyana Suhan; Jaroslav Cinatl; Roman A Blaheta; Katrin Hoffmann; Rouslan Kotchetkov; Rudi Busse; Heinz Nau; Jindrich Cinatl
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

Review 8.  Angiogenesis--a new target for future therapy.

Authors:  Nilesh M Pandya; Naranjan S Dhalla; Dev D Santani
Journal:  Vascul Pharmacol       Date:  2006-03-20       Impact factor: 5.773

9.  Histone deacetylase is a target of valproic acid-mediated cellular differentiation.

Authors:  Nadia Gurvich; Oxana M Tsygankova; Judy L Meinkoth; Peter S Klein
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

10.  Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.

Authors:  Caroline L Benn; Rachel Butler; Lydia Mariner; Jude Nixon; Hilary Moffitt; Michal Mielcarek; Ben Woodman; Gillian P Bates
Journal:  PLoS One       Date:  2009-06-01       Impact factor: 3.240

View more
  17 in total

1.  Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.

Authors:  Zhifei Wang; Li-Kai Tsai; Jeeva Munasinghe; Yan Leng; Emily Bame Fessler; Fairouz Chibane; Peter Leeds; De-Maw Chuang
Journal:  Stroke       Date:  2012-07-17       Impact factor: 7.914

Review 2.  Hemodynamics mediated epigenetic regulators in the pathogenesis of vascular diseases.

Authors:  C L Karthika; S Ahalya; N Radhakrishnan; C C Kartha; S Sumi
Journal:  Mol Cell Biochem       Date:  2020-08-25       Impact factor: 3.396

3.  Sodium valproate ameliorates memory impairment and reduces the elevated levels of apoptotic caspases in the hippocampus of diabetic mice.

Authors:  Parvin Zareie; Mahsa Gholami; Behnam Amirpour-Najafabadi; Sirvan Hosseini; Mehdi Sadegh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-04       Impact factor: 3.000

Review 4.  Epigenetics in the Vascular Endothelium: Looking From a Different Perspective in the Epigenomics Era.

Authors:  Matthew S Yan; Philip A Marsden
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-24       Impact factor: 8.311

5.  Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and convergent mechanisms of regulation in diabetes.

Authors:  Haloom Rafehi; Antony Kaspi; Mark Ziemann; Jun Okabe; Tom C Karagiannis; Assam El-Osta
Journal:  Epigenetics       Date:  2017       Impact factor: 4.528

Review 6.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

Review 7.  The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.

Authors:  Saikat Dewanjee; Jayalakshmi Vallamkondu; Rajkumar Singh Kalra; Pratik Chakraborty; Moumita Gangopadhyay; Ranabir Sahu; Vijaykrishna Medala; Albin John; P Hemachandra Reddy; Vincenzo De Feo; Ramesh Kandimalla
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

8.  Targeting p35/Cdk5 signalling via CIP-peptide promotes angiogenesis in hypoxia.

Authors:  Alessandra Bosutti; Jie Qi; Roberta Pennucci; David Bolton; Sabine Matou; Kamela Ali; Li-Huei Tsai; Jerzy Krupinski; Eugene B Petcu; Joan Montaner; Raid Al Baradie; Francesca Caccuri; Arnaldo Caruso; Giulio Alessandri; Shant Kumar; Cristina Rodriguez; Jose Martinez-Gonzalez; Mark Slevin
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

Review 9.  Endothelial heterogeneity in the umbilico-placental unit: DNA methylation as an innuendo of epigenetic diversity.

Authors:  Paola Casanello; Daniela Schneider; Emilio A Herrera; Ricardo Uauy; Bernardo J Krause
Journal:  Front Pharmacol       Date:  2014-03-27       Impact factor: 5.810

10.  HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury.

Authors:  Dietrich A Ruess; Moriz Probst; Goran Marjanovic; Uwe A Wittel; Ulrich T Hopt; Tobias Keck; Dirk Bausch
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.